Flagship Pioneering London Lab: £100M Bet on AI-Native Biotech
Flagship Pioneering commits £100M to a London Origination Lab to build AI-native biotech companies, its first outside the US, with a £500M partner target.
Flagship Pioneering commits £100M to a London Origination Lab to build AI-native biotech companies, its first outside the US, with a £500M partner target.
Five years of continuous lecanemab left patients 2.05 CDR-SB points better than an untreated cohort, while ARIA risk fell after year one. What the CTAD 2026 data mean for Eisai and Biogen.
A previously undisclosed raid on an illegal vape factory in Chino, California, recovered about 850,000 Geek Bar and Foger vapes and parts. What it means.
Seawolf Therapeutics debuts with $100M and a Sanofi pact worth up to $1.2B to develop non-viral DNA medicines for bleeding disorders. What TRIDENT promises and what is unproven.
Teva has reached an agreement in principle with 45 states, DC and two territories over alleged generic drug price-fixing. Terms are undisclosed; here is what is known.
Gedeon Richter will pay A$6.40 a share, about A$604 million, for Mayne Pharma, a 99% premium that gives the Hungarian drugmaker a US women’s health business.
Eli Lilly signed a multi-target oncology pact with Stipple Bio worth up to $5.9 billion in milestones. We break down the terms, the Pointillist platform and the ADC market it targets.
Eli Lilly will pay up to $1.5 billion for Calytrix Bio and its preclinical mutant-CALR antibody for essential thrombocythemia and myelofibrosis.
J&J will pay $2.2B upfront for Ollin Biosciences and its VEGF/Ang2 eye drug OLN324, with Blackstone funding $750M of Phase 3. Terms, science and risks.